Author details

Full Name

Jean-Claude Marshall

Affiliation

ORCID

Career Start Year

2004

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34081195	Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG).	Human Genetics	2022
36083119	Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.	New England Journal of Medicine	2022
33813736	Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.	Journal of Clinical Pharmacology	2021
33955129	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.	Oncologist	2021
31123759	Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.	European Journal of Clinical Pharmacology	2019
31648530	Bioanalysis of adeno-associated virus gene therapy therapeutics: regulatory expectations.	Bioanalysis	2019
30340248	Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.	British Journal of Clinical Pharmacology	2019
30192390	No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.	Journal of Clinical Pharmacology	2019
30633368	Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology.	Journal of Clinical Pharmacology	2019
29572563	Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.	European Journal of Clinical Pharmacology	2018
26616152	The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).	Pharmacogenomics	2015
24456465	Toward more transparent and reproducible omics studies through a common metadata checklist and data publications.	OMICS	2014
23154488	The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.	Eye	2013
27447251	Toward More Transparent and Reproducible Omics Studies Through a Common Metadata Checklist and Data Publications.	Big Data	2013
22760522	Dipyridamole prevents triple-negative breast-cancer progression.	Clin Exp Metastasis	2013
23940300	Nm23-h1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis.	Cancer Res	2013
24147068	Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.	PLoS One	2013
22911670	Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.	J Natl Cancer Inst	2012
21713383	Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1.	Naunyn Schmiedebergs Arch Pharmacol	2011
20304626	The Nm23-H1 metastasis suppressor as a translational target.	Eur J Cancer	2010
19823872	Expression profiling of formalin-fixed paraffin embedded primary human uveal melanomas using DASL matrices.	Journal of Cancer Research and Clinical Oncology	2010
18827739	Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients.	Retina	2009
19351402	The effect of blue light exposure in an ocular melanoma animal model.	Journal of Experimental and Clinical Cancer Research	2009
19387797	Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression.	Mol Cell Biochem	2009
19661316	SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation.	Anticancer Research	2009
19415462	Altered gene and protein expression by Nm23-H1 in metastasis suppression.	Mol Cell Biochem	2009
19820792	Fine needle aspiration biopsy to reestablish cell culture in an animal model of uveal melanoma.	Arquivos Brasileiros de Oftalmologia	2009
18219339	Expression of the metastasis suppressor gene KISS1 in uveal melanoma.	Eye	2008
18049486	Amfenac increases the radiosensitivity of uveal melanoma cell lines.	Eye	2008
18246031	Immunomagnetic isolation and in vitro expansion of human uveal melanoma cell lines.	Molecular Vision	2008
18245548	Immune expression and inhibition of heat shock protein 90 in uveal melanoma.	Clinical Cancer Research	2008
18834404	The role of metastasis suppressor genes in metastatic dormancy.	APMIS	2008
18335317	Single-cell tumor dormancy model of uveal melanoma.	Clinical and Experimental Metastasis	2008
18281525	Molecular pathways mediating liver metastasis in patients with uveal melanoma.	Clinical Cancer Research	2008
18001467	In vitro characterization and inhibition of the CXCR4/CXCL12 chemokine axis in human uveal melanoma cell lines.	Cancer Cell International	2007
17591671	Expression of C-kit in retinoblastoma: a potential therapeutic target.	British Journal of Ophthalmology	2007
17261188	Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF.	Journal of Carcinogenesis	2007
17885583	Expression of nm23-H1 in uveal melanoma.	Melanoma Research	2007
17487557	Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis.	Clinical and Experimental Metastasis	2007
17434930	The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma.	Carcinogenesis	2007
18042295	The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.	Journal of Carcinogenesis	2007
17119455	The effect of blue light exposure and use of intraocular lenses on human uveal melanoma cell lines.	Melanoma Research	2006
16123787	The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferation rate of retinoblastoma cell lines.	Eye	2006
16751051	Blue light exposure and uveal melanoma.	Ophthalmology	2006
16236162	The role of c-kit and imatinib mesylate in uveal melanoma.	J Carcinog	2005
15917694	Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions.	Melanoma Research	2005
16303923	Characterization of ocular and metastatic uveal melanoma in an animal model.	Investigative Ophthalmology and Visual Science	2005
15057037	Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro.	Melanoma Research	2004
15457100	Cytotoxic effects of violacein in human uveal melanoma cell lines.	Melanoma Research	2004
15459482	Cell proliferation profile of five human uveal melanoma cell lines of different metastatic potential.	Pathobiology	2004